chufangao/CTO huggingface dataset:
Clinical trial NCT03500484: Effect of Liraglutide on Neural Responses to High Fructose Corn Syrup in Individuals With Obesity.
Official title: Effect of Liraglutide on Neural Responses to High Fructose Corn Syrup in Individuals With Obesity.
Sponsor: Yale University (OTHER)
Study type: INTERVENTIONAL
Phase: EARLY_PHASE1
Status: TERMINATED 
Why stopped: The study was initially paused due to COVID restrictions and then when able to resume, there was no longer funding.
Enrollment: 13.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-06-06
Primary completion date: 2020-06-25
Completion date: 2020-06-25
Clinical trial NCT03532009: Potassium Reduction Initiative to Optimize RAAS Inhibition Therapy With Sodium Zirconium Cyclosilicate in Heart Failure
Official title: A Phase II, Randomised, Double-Blind, Placebo Controlled, Parallel-Group, Multicentre, Three Month Duration Potassium Reduction Initiative to Optimize RAAS Inhibition Therapy With Sodium Zirconium Cyclosilicate in Heart Failure
Acronym: PRIORITIZE HF
Sponsor: AstraZeneca (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Study stopped early due to the COVID-19 pandemic
Enrollment: 182.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-06-26
Primary completion date: 2020-05-22
Completion date: 2020-05-22
Limitations and caveats: The study was paused from May to October 2019 to undergo a major protocol amendment. The study was also prematurely terminated due to the COVID-19 pandemic resulting in a reduced sample size and a high premature treatment discontinuation rate.
Plan to share individual participant data: YES
IPD sharing description: Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.~Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.
IPD time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
IPD access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Clinical trial NCT04026464: Addition of Acetaminophen in Standard PDA Management
Official title: Monotherapy (Ibuprofen) vs. Combination Therapy (Ibuprofen and Acetaminophen) in the Management of Patent Ductus Arteriosus in Premature Infants: A Randomized Controlled Trial
Sponsor: University of Florida (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: Unable to obtain funding to support this project
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-04-30
Primary completion date: 2021-05-12
Completion date: 2021-05-12
Plan to share individual participant data: NO
Clinical trial NCT04771000: A Study of Micro Dose Ambrisentan in Hospitalized Patients With Respiratory Insufficiency Due to COVID-19
Official title: A Randomised, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy and Safety of Ambrisentan in Patients With Severe COVID-19
Sponsor: Noorik Biopharmaceuticals AG (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Lack of recruitment
Enrollment: 88.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-02-08
Primary completion date: 2023-02-27
Completion date: 2023-02-27
Plan to share individual participant data: UNDECIDED
IPD sharing description: Not yet discussed or decided
Clinical trial NCT03224208: Vemurafenib Plus Cobimetinib in Advanced or Metastatic Melanoma Patients
Official title: VECODUE A Phase II Trial of Vemurafenib Plus Cobimetinib in Patients Treated With Prior First-line Systemic Immunotherapy for Inoperable Locally Advanced or Metastatic Melanoma
Acronym: VECODUE
Sponsor: Fondazione Melanoma Onlus (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: low enrolment rate
Enrollment: 9.0 (ACTUAL)
Number of arms: 1.0
Start date: 2018-05-17
Primary completion date: 2020-09-12
Completion date: 2021-01-08
Plan to share individual participant data: NO
Clinical trial NCT04590274: Safety and Efficacy of Hydroxychloroquine for the Treatment & Prevention of Coronavirus Disease 2019 (COVID-19) Caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
Official title: Safety and Efficacy of Hydroxychloroquine for the Treatment & Prevention of Coronavirus Disease 2019 (COVID-19) Caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
Sponsor: International Brain Research Foundation (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: WITHDRAWN 
Why stopped: Investigative Team no longer interested
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2020-11-30
Primary completion date: 2021-12-31
Completion date: 2021-12-31
Clinical trial NCT04128007: Safety and Efficacy of ARQ-154 Foam in Adolescent and Adult Subjects With Scalp and Body Psoriasis
Official title: A Phase 2b, 8-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-154 Foam 0.3% Administered QD in Adolescents and Adults With Scalp and Body Psoriasis
Sponsor: Arcutis Biotherapeutics, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 304.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-01-13
Primary completion date: 2020-09-23
Completion date: 2020-09-25
Plan to share individual participant data: NO
Clinical trial NCT03980483: Efficacy and Safety of GSK3196165 Versus Placebo and Tofacitinib in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate
Official title: A 52-week, Phase 3, Multicentre, Randomised, Double Blind, Efficacy and Safety Study Comparing GSK3196165 With Placebo and With Tofacitinib, in Combination With Methotrexate in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate
Acronym: contRAst 1
Sponsor: GlaxoSmithKline (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 1537.0 (ACTUAL)
Number of arms: 6.0
Start date: 2019-05-16
Primary completion date: 2021-09-15
Completion date: 2022-08-16
Plan to share individual participant data: YES
IPD sharing description: IPD for this study will be made available via the Clinical Study Data Request site.
IPD time frame: IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study.
IPD access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.
Clinical trial NCT04714619: CB-103 Plus NSAI In Luminal Advanced Breast Cancer
Official title: CB-103 Plus NSAI In Luminal Advanced Breast Cancer: CAILA Study
Acronym: CAILA
Sponsor: MedSIR (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Sponsor decision
Enrollment: 2.0 (ACTUAL)
Number of arms: 1.0
Start date: 2021-05-06
Primary completion date: 2021-09-02
Completion date: 2022-04-26
Plan to share individual participant data: NO
Clinical trial NCT05346120: Post-Acute COVID-19, Inflammation, and Depression
Official title: Post-Acute COVID-19, Inflammation, and Depression
Acronym: COVID Long
Sponsor: The University of Texas Health Science Center, Houston (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: Study never started
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2022-05-25
Primary completion date: 2023-12-20
Completion date: 2024-05-01
Plan to share individual participant data: NO
Clinical trial NCT03992196: A Follow-up Study of Rotigotine Patch in Adolescent Subjects With Restless Legs Syndrome
Official title: A Remote, Open-Label, Long-Term, Follow-up Study to Determine the Safety, Tolerability, and Efficacy of Rotigotine Transdermal System as Monotherapy in Adolescents With Restless Legs Syndrome
Sponsor: UCB Pharma (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: Sponsor decision; Not a safety decision
Enrollment: 10.0 (ACTUAL)
Number of arms: 1.0
Start date: 2019-12-03
Primary completion date: 2022-09-01
Completion date: 2022-09-01
Baseline population: The Safety Set consisted of all participants who had at least one patch (rotigotine) applied. Due to data protection/data privacy, data cannot be reported for a single participant.
Plan to share individual participant data: YES
IPD sharing description: Data from this study may be requested by qualified researchers six months after product approval in the US and/or Europe, or global development is discontinued, and 18 months after trial completion. Investigators may request access to anonymized IPD and redacted study documents which may include: raw datasets, analysis-ready datasets, study protocol, blank case report form, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.clinicalstudydatarequest.com and a signed data sharing agreement will need to be executed. All documents are available in English only, for a pre-specified time, typically 12 months, on a password protected portal. This plan may change if a determination is made that the data cannot be adequately anonymized.
IPD time frame: Data from this study may be requested by qualified researchers six months after product approval in the US and/or Europe or global development is discontinued, and 18 months after trial completion.
IPD access criteria: Qualified researchers may request access to anonymized IPD and redacted study documents which may include: raw datasets, analysis-ready datasets, study protocol, blank case report form, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.clinicalstudydatarequest.com and a signed data sharing agreement will need to be executed. All documents are available in English only, for a pre-specified time, typically 12 months, on a password protected portal.
Clinical trial NCT03504852: Efficacy and Safety of 2 Secukinumab Regimens in 90kg or More Weight Group With Moderate/Severe Chronic Plaque Psoriasis
Official title: A Randomized, Double-blind, Multicenter Study Assessing Short and Long-term Efficacy, Safety, and Tolerability of Sub-cutaneous Secukinumab in Subjects of Body Weight 90 kg or Higher With Moderate to Severe Chronic Plaque-type Psoriasis
Sponsor: Novartis (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 331.0 (ACTUAL)
Number of arms: 3.0
Start date: 2018-06-25
Primary completion date: 2019-09-13
Completion date: 2020-07-15
Plan to share individual participant data: YES
IPD sharing description: Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com.
Clinical trial NCT04393506: Inductive Camrelizumab and Apatinib for Patients With Locally Advanced and Resectable Oral Squamous Cell Carcinoma
Official title: Inductive Camrelizumab and Apatinib for Patients With Locally Advanced and Resectable Oral Squamous Cell Carcinoma: A Single-arm Phase I Trial
Sponsor: Shanghai Jiao Tong University School of Medicine (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: COMPLETED 
Enrollment: 21.0 (ACTUAL)
Number of arms: 1.0
Start date: 2020-04-23
Primary completion date: 2020-11-02
Completion date: 2023-11-10
Plan to share individual participant data: NO
Clinical trial NCT03358875: Comparison of Efficacy and Safety of Anti-PD-1 Antibody BGB-A317 Versus Docetaxel as Treatment in the Second- or Third-line Setting in Participants With NSCLC
Official title: A Phase 3, Open-Label, Multicenter, Randomized Study to Investigate the Efficacy and Safety of BGB-A317 (Anti-PD1 Antibody) Compared With Docetaxel in Patients With Non-Small Cell Lung Cancer Who Have Progressed on a Prior Platinum-Containing Regimen
Sponsor: BeiGene (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 805.0 (ACTUAL)
Number of arms: 2.0
Start date: 2017-11-30
Primary completion date: 2020-08-10
Completion date: 2024-01-18
Plan to share individual participant data: YES
Clinical trial NCT05227456: Failed Endometrial Ablation Treatment With Implantable Progesterone (FEAT) Study
Official title: Failed Endometrial Ablation Treatment With Implantable Progesterone (FEAT) Study
Acronym: FEATS
Sponsor: Saskatchewan Health Authority - Regina Area (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Difficulty in Recruitment
Enrollment: 3.0 (ACTUAL)
Number of arms: 1.0
Start date: 2022-07-01
Primary completion date: 2024-04-30
Completion date: 2024-04-30
Clinical trial NCT05470387: A Study to Evaluate LB1148 for Return of Bowel Function in Subjects Undergoing Bowel Resection
Official title: A Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Safety and Efficacy of LB1148 in Accelerating the Time to Return of Bowel Function in Subjects Undergoing Planned Bowel Resection (INTEGRITY)
Acronym: INTEGRITY
Sponsor: Palisade Bio (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: Company decision
Enrollment: 23.0 (ACTUAL)
Number of arms: 2.0
Start date: 2022-06-28
Primary completion date: 2023-03-06
Completion date: 2023-08-11
Plan to share individual participant data: NO
Clinical trial NCT05666349: Reirradiation and Niraparib in Patients With Recurrent Glioblastoma
Official title: Reirradiation (Re-RT) and Niraparib (NIRA) in Patients With Recurrent Glioblastoma (rGBM)
Acronym: RiNG
Sponsor: University College, London (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: WITHDRAWN 
Why stopped: Funder support withdrawn 13-Oct-2023. Study did not open to recruitment.
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2023-10-13
Primary completion date: 2023-10-13
Completion date: 2023-10-13
Plan to share individual participant data: NO
Clinical trial NCT05448677: Ezurpimtrostat Autophagy Inhibitor in Association With Atezolizumab-Bevacizumab in First Line Treatment of Unresectable Hepatocellular Carcinoma
Official title: Ezurpimtrostat Autophagy Inhibitor in Association With Atezolizumab-Bevacizumab in First Line Treatment of Unresectable Hepatocellular Carcinoma, a Phase 2b Randomized Trial
Acronym: ABE-LIVER
Sponsor: University Hospital, Grenoble (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Study terminated due to recruitement issues
Enrollment: 3.0 (ACTUAL)
Number of arms: 2.0
Start date: 2022-12-15
Primary completion date: 2024-03-08
Completion date: 2024-03-08
Plan to share individual participant data: NO
Clinical trial NCT02343120: Study of the Safety and Pharmacokinetics of BGB-3111 in Subjects With B-Cell Lymphoid Malignancies
Official title: A Phase I/II, Open-Label, Multiple-Dose, Dose Escalation and Expansion Study to Investigate the Safety and Pharmacokinetics of the BTK Inhibitor BGB-3111 in Subjects With B-Cell Lymphoid Malignancies
Sponsor: BeiGene (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: COMPLETED 
Enrollment: 385.0 (ACTUAL)
Number of arms: 1.0
Start date: 2014-09-04
Primary completion date: 2021-03-31
Completion date: 2021-03-31
Baseline population: The Safety Analysis Set included all participants who received ≥ 1 dose of study drug
Clinical trial NCT03400306: A Study Evaluating the Bioavailability and Food Effect of Veliparib Tablets Followed by an Extension in Subjects With Ovarian Cancer
Official title: A Phase 1, Single-Dose, Open-Label, Randomized Cross-Over Study Evaluating the Bioavailability and Food Effect of Veliparib Tablets Followed by an Extension in Subjects With Ovarian Cancer
Sponsor: AbbVie (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: WITHDRAWN 
Why stopped: Strategic considerations
Enrollment: 0.0 (ACTUAL)
Number of arms: 3.0
Start date: 2021-11-15
Primary completion date: 2021-11-16
Completion date: 2021-11-16
Plan to share individual participant data: NO
Clinical trial NCT03001557: Study of Lemborexant for Irregular Sleep-Wake Rhythm Disorder and Mild to Moderate Alzheimer's Disease Dementia
Official title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study With Open-Label Extension Phase of the Efficacy and Safety of Lemborexant in Subjects With Irregular Sleep-Wake Rhythm Disorder and Mild to Moderate Alzheimer's Disease Dementia
Sponsor: Eisai Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 63.0 (ACTUAL)
Number of arms: 5.0
Start date: 2016-12-20
Primary completion date: 2018-07-26
Completion date: 2020-04-17
Baseline population: The safety analysis set included the group of randomized participants who received at least 1 dose of randomized study drug and had at least 1 postdose safety assessment.
Clinical trial NCT05275400: A Study of Insulin Efsitora Alfa (LY3209590) Compared With Insulin Degludec in Participants With Type 2 Diabetes Currently Treated With Basal Insulin
Official title: A Phase 3, Multicenter, Randomized, Parallel-Design, Open-Label Trial to Evaluate the Efficacy and Safety of LY3209590 Compared With Insulin Degludec in Participants With Type 2 Diabetes Currently Treated With Basal Insulin (QWINT-3)
Sponsor: Eli Lilly and Company (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 986.0 (ACTUAL)
Number of arms: 2.0
Start date: 2022-03-08
Primary completion date: 2024-05-15
Completion date: 2024-05-15
Plan to share individual participant data: YES
IPD sharing description: Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
IPD time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and European Union (EU), whichever is later. Data will be indefinitely available for requesting.
IPD access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
Clinical trial NCT04895410: Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Lemzoparlimab With or Without Oral/IV Dexamethasone and in Combination With Oral/IV/Subcutaneous Anti-Myeloma Regimens in Adult Participants With Multiple Myeloma
Official title: A Phase 1b, Dose Escalation and Expansion Study of Lemzoparlimab With or Without Dexamethasone and in Combination With Anti-Myeloma Regimens for the Treatment of Patients With Relapsed/Refractory Multiple Myeloma
Sponsor: AbbVie (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Strategic considerations
Enrollment: 8.0 (ACTUAL)
Number of arms: 9.0
Start date: 2022-01-17
Primary completion date: 2022-06-24
Completion date: 2022-06-24
Plan to share individual participant data: NO
Clinical trial NCT04826588: Randomised Evaluation of COVID-19 Therapy (RECOVERY) in Children With PIMS-TS in Switzerland (SWISSPED-RECOVERY)
Official title: Randomised Evaluation of COVID-19 Therapy (RECOVERY) in Children With PIMS-TS in Switzerland (SWISSPED-RECOVERY)
Sponsor: University Children's Hospital Basel (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 76.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-05-23
Primary completion date: 2022-11-20
Completion date: 2022-11-20
Clinical trial NCT04099888: PCI Treatment/Gemcitabine & Chemotherapy vs Chemotherapy Alone in Patients With Inoperable Extrahepatic Bile Duct Cancer
Official title: A Multi-Center Randomised Open-Label Phase 2 Study to Assess the Safety, Tolerability and Efficacy of Fimaporfin-Induced Photochemical Internalisation of Gemcitabine Complemented by Gemcitabine/Cisplatin Chemotherapy Versus Gemcitabine/Cisplatin Alone in Patients With Inoperable Cholangiocarcinoma
Acronym: RELEASE
Sponsor: PCI Biotech AS (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Recent results from a Phase 3 study are expected to change the standard of care for patients with inoperable CCA, rendering the RELEASE study challenging to complete and potentially inadequate for NDA approval.
Enrollment: 41.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-05-23
Primary completion date: 2022-04-28
Completion date: 2022-05-06
Baseline population: Intent-to-treat (ITT) Analysis Set
Limitations and caveats: Due to the early termination of this study, no definitive conclusions can be drawn since an insufficient number of participants was recruited. A reduced statistical analysis was conducted.
Plan to share individual participant data: NO
Clinical trial NCT03335371: Evaluation of TTP399 in Patients With Type 1 Diabetes
Official title: A Multi-Center, Randomized, Double-Blind, Parallel-Group, Multiple-Dose, Adaptive Study Assessing the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of TTP399 in With Adult Patients Type 1 Diabetes Mellitus
Acronym: SimpliciT1
Sponsor: vTv Therapeutics (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: COMPLETED 
Enrollment: 115.0 (ACTUAL)
Number of arms: 2.0
Start date: 2017-10-25
Primary completion date: 2019-12-20
Completion date: 2020-01-06
Baseline population: Sentinel participants were the same participants throughout the dose levels. Part 1 is the full analysis set. Part 2 is all randomized subjects who received at least 1 dose of the investigational product.
Plan to share individual participant data: NO
Clinical trial NCT04564846: A Study to Evaluate the Effect of ORMD-0801 in Patients With Type 2 Diabetes Mellitus
Official title: A Randomized, Double Blind, Phase 2b Study to Evaluate the Effect of ORMD-0801 Compared to Placebo on Endogenous Glucose Production in Patients With Type 2 Diabetes Mellitus
Sponsor: Oramed, Ltd. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 49.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-11-23
Primary completion date: 2022-06-07
Completion date: 2022-06-07
Plan to share individual participant data: NO
Clinical trial NCT04551885: FT516 in Combination With Monoclonal Antibodies in Advanced Solid Tumors
Official title: A Phase I, Open-Label, Multicenter Study of FT516 in Combination With Monoclonal Antibodies in Subjects With Advanced Solid Tumors
Sponsor: Fate Therapeutics (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: This study was terminated by the Sponsor.
Enrollment: 12.0 (ACTUAL)
Number of arms: 1.0
Start date: 2020-09-07
Primary completion date: 2023-08-11
Completion date: 2023-08-11
Plan to share individual participant data: NO